What smart money is saying about Eli Lilly and Company
9 funds in our archive have pitched Eli Lilly and Company — most recently Baron Health Care Fund in June 2026.
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Get an email when a fund writes about it
Position history
Between Q4 2024 and Q2 2026, 18 fund letters reported a position in Eli Lilly and Company — 5 opened or added to the position, 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 16 | 5 | 1 | 2 |
| Q1 2026 | 2 | 0 | 0 | 2 |
| Q4 2025 | 0 | 0 | 0 | 2 |
| Q2 2025 | 0 | 0 | 0 | 1 |
| Q1 2025 | 0 | 0 | 0 | 1 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Fund activity · 18 positions · 6 moves
- June 2026
Listed in Royal London AM Global Equity Diversified Fund’s reported holdings.
Eli Lilly and Company - June 2026
“Health care performance was more mixed, with a wide dispersion of outcomes within the portfolio. Argenx, West Pharmaceutical and Eli Lilly were among the strongest contributors, benefiting from company-specific profit cycles tied to differentiated therapies, improving demand visibility and solid execution.”
Eli Lilly and Company - June 2026
“Transactions during the quarter included the purchase of new positions in Lockheed Martin and NVIDIA. These trades, alongside some additions to energy and consumer-linked holdings, were funded through exiting our positions in Broadcom and Eli Lilly and by trimming a broad range of AI compute beneficiaries.”
Eli Lilly and Company - June 2026
Listed in Royal London AM Royal London US Equity Trust’s reported holdings.
Eli Lilly and Company - June 2026
“Top contributors to performance for the quarter Contribution to Return (%) Eli Lilly and Company 3.70 BillionToOne, Inc. 1.06 argenx SE 0.98 Roivant Sciences Ltd. 0.95 Guardant Health, Inc. 0.90 Pharmaceutical company Eli Lilly and Company , currently best known for its diabetes and obesity GLP-1 therapies, contributed to performance as commercial execution and pipeline data reinforced investor confidence in the company's long-term leadership.”
Eli Lilly and Company - HoldsBaron Partners FundJune 2026
Listed in Baron Partners Fund’s reported holdings.
Eli Lilly and Company - June 2026
Listed in Baron Opportunity Strategy’s reported holdings.
Eli Lilly and Company - June 2026
Listed in Buffalo funds Blue Chip Growth Fund’s reported holdings.
Eli Lilly and Company - June 2026
“We added to Eli Lilly & Company in the second quarter as we believe it remains a compelling big idea. Eli Lilly is best known for its GIP/GLP-1 medications for diabetes and obesity.”
Eli Lilly and Company - HoldsBaron Partners FundJune 2026
Listed in Baron Partners Fund’s reported holdings.
Eli Lilly and Company Listed in Jensen Investment Management Quality Growth Equity Composite’s reported holdings.
Eli Lilly and Company- June 2026
Listed in Liontrust Global Innovation Fund’s reported holdings.
Eli Lilly and Company - June 2026
Listed in Liontrust GF Global Innovation Fund’s reported holdings.
Eli Lilly and Company - June 2026
“Beyond technology, Eli Lilly (+30%) sold $8.66 billion of a single medicine in the quarter. Mounjaro, for type 2 diabetes, grew 125% year on year; Zepbound, for obesity, added $4.16 billion in the US alone, up 80%; and Foundayo, the first oral GLP-1 at scale, recorded 20,000 prescriptions in its first 20 days, 80% from patients new to GLP-1 therapy. Group revenue grew 56% to $19.8 billion, EPS rose 156% to $8.55 on a non GAAP basis, and full year revenue guidance was raised to $82 to $85 billion. Lilly holds 60.1% of the US obesity and diabetes market against Novo Nordisk’s 39.4%. Here the dislocation ran the other way: we added through the quarter; at 4.2% Lilly ended the period among the Fund’s largest holdings, having just raised its dividend 15% for 2026, an eleventh consecutive annual increase.”
Eli Lilly and Company - HoldsBaron CapitalJune 2026
Listed in Baron Capital’s reported holdings.
Eli Lilly and Company - June 2026
“Beyond technology, Eli Lilly (+30%) sold $8.66 billion of a single medicine in the quarter. Mounjaro, for type 2 diabetes, grew 125% year on year; Zepbound, for obesity, added $4.16 billion in the US alone, up 80%; and Foundayo, the first oral GLP-1 at scale, recorded 20,000 prescriptions in its first 20 days, 80% from patients new to GLP-1 therapy. Group revenue grew 56% to $19.8 billion, EPS rose 156% to $8.55 on a non GAAP basis, and full year revenue guidance was raised to $82 to $85 billion. Lilly holds 60.1% of the US obesity and diabetes market against Novo Nordisk’s 39.4%. Here the dislocation ran the other way: we added through the quarter; at 4.2% Lilly ended the period among the Fund’s largest holdings, having just raised its dividend 15% for 2026, an eleventh consecutive annual increase.”
Eli Lilly and Company - March 2026
Listed in Buffalo Blue Chip Growth Fund’s reported holdings.
Eli Lilly and Company - March 2026
“Eli Lilly and Company: LLY was a top detractor for the quarter, declining 14% as the pharmaceutical sector faced an intensifying regulatory and pricing policy environment.”
Eli Lilly and Company
Fund coverage · 9 theses
- Baron Health Care FundJune 2026
Eli Lilly leads in diabetes and obesity therapies, supported by broad coverage, strong clinical data, and a top-tier metabolic pipeline.
Read the full thesis - Baron Fifth Avenue Growth FundJune 2026
Eli Lilly and Company is a leader in GLP-1 drugs with massive underpenetration, strong pipeline optionality, and long-term growth potential.
Read the full thesis - Artisan Global Opportunities StrategyMarch 2026
Eli Lilly is a GLP-1 leader poised to drive accelerating obesity volumes with Foundayo and broader coverage amid strong category demand and limited cannibalization.
Read the full thesis Eli Lilly is viewed as a premier healthcare growth franchise with leadership in obesity and diabetes and strong multi-year revenue growth.
Read the full thesis- Baron Health Care FundDecember 2025
Eli Lilly and Company is a leading pharmaceutical firm with transformative GLP-1 therapies driving a massive obesity/diabetes opportunity and expected revenue doubling by 2030.
Read the full thesis - Baron Opportunity FundDecember 2025
Eli Lilly and Company is a leading GLP-1 drug developer with expanding reimbursement and a large obesity/diabetes market that could nearly double revenues by 2030.
Read the full thesis - Baron Health Care FundJune 2025
Eli Lilly and Company is positioned to dominate the growing GLP-1 market for diabetes and obesity, with innovative drugs expected to triple its revenues by 2030.
Read the full thesis - Liontrust GF Global Innovation FundMarch 2025
Eli Lilly is well-positioned for strong returns due to robust financials, a growing GLP-1 market, and a promising oral GLP-1 portfolio, despite recent fluctuations and competition.
Read the full thesis - Aristotle Focus GrowthDecember 2024
Eli Lilly is a leading pharmaceutical company with a strong pipeline in diabetes, oncology, and immunology, poised for growth through innovative treatments and a premium valuation supported by its successful drug portfolio.
Read the full thesis
Read every full thesis on Eli Lilly and Company
Unlock all 9 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→